title: Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?
authors.forename: Carmen
authors.initials: C
authors.lastname: Balañá
authors.forename: Olatz
authors.initials: O
authors.lastname: Etxaniz
authors.forename: Cristina
authors.initials: C
authors.lastname: Bugés
authors.forename: Alex
authors.initials: A
authors.lastname: Martínez
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D005060:Europe; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab